Sava Infond d.o.o. Takes Position in Novo Nordisk A/S (NYSE:NVO)

Sava Infond d.o.o. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 18,500 shares of the company's stock, valued at approximately $1,591,000.

Other hedge funds also recently made changes to their positions in the company. Center for Financial Planning Inc. lifted its position in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Albion Financial Group UT boosted its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Sound Income Strategies LLC grew its holdings in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after purchasing an additional 243 shares during the last quarter. Finally, Hager Investment Management Services LLC purchased a new position in Novo Nordisk A/S in the 4th quarter worth $46,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NVO. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $145.25.

Remove Ads

Novo Nordisk A/S Stock Down 1.1 %

Shares of Novo Nordisk A/S stock traded down $0.81 during trading on Friday, hitting $69.36. The company's stock had a trading volume of 5,852,065 shares, compared to its average volume of 5,563,763. Novo Nordisk A/S has a 52 week low of $69.18 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a fifty day simple moving average of $82.33 and a two-hundred day simple moving average of $98.89. The company has a market capitalization of $311.23 billion, a PE ratio of 21.08, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.